we awaiting quarter, for programs. in clinical second advanced programs, the In delivered exciting potentially We first-in-class X designation everyone. received our of afternoon, breakthrough or broad therapy additional many good a while data rapidly eagerly quarter, clinical best-in-class readouts and Vikram, this data later year. you, Thank pipeline and approvals the
begin Let's medicine. general with
profile based top line will it mentioned, conditions confident are X data XX-week seeing on from track the in are address previously Type obesity, II ongoing needs important As interim a remain with Phase MariTide and and XXXX. in late look MariTide obesity-related and analysis, on diabetes. medical the to we We study differentiated unmet forward
planning a treatment obesity. obesity, trial obesity-related and for of III along MariTide investigating patients and broad in the a diabetes actively are expect initiate with diabetes, in program We and to II Phase with without Phase conditions
of early our both non-accreting progress to programs obesity continue consists oral and we and approaches. injectable that MariTide, incretin Beyond
To development outcomes of this Olpasiran interfering risk whom genetically Lp(a) Olpasiran, progress. one for enrolled programs no medicine, exist. continues or small expect in therapies of our targeted med best-in-class cardiovascular year. approximately Also is the and clinical remind, in is that is cardiovascular of to factor RNA trial fully XX% Gen targeting later Lp(a) Phase to III enter We defined individuals effective currently elevated a these potentially
with patients. to In conviction on therapies clinical differentiated for oncology, we continue transformative capable high benefit deliver targets delivering of
platinum-based the that approval lung engager IMDELLTRA, adult BiTE or small bispecific chemotherapy. treatment patients extensive DLLX granted of cell with to small begin targeting cancer. for a We're lung very T cell with FDA molecule the on progression pleased cancer disease after accelerated stage for IMDELLTRA Let's with or first-in-class cell
extensive Phase interval with activity with a we patients greater X advancing option agent we a Based to as months. the in on guidelines months are X been an observed second that than patients and preferred X other limited and with therapy equal updated less frontline patients as pleased treatment option a interval IMDELLTRA in recommended single underway than the a include have IMDELLTRA into NCCN both III and studies third-line Further, for or receiving as chemotherapy-free to are remarkable disease. chemotherapy-free therapy, rapidly for stage
tarlatimab tumor. Phase lines draws in studies, cancer first a burden, has the second-line The our our tumor One and solid lower engager earlier small leukemia. Notably, bispecific T experience B-cell is present study cell III in with of IMDELLTRA confirmatory XXX, to first and DeLLphi- treat completed engager approved lung of in of bispecific these lipoblastic from approved cell common study context enrollment. the cell acute our BLINCYTO T
Here, finding we tolerability. are drivers that means evidence observed These in eliminating dramatic T this survival occurrence. along cell patients, of cancer with of disease improvement overall that an the effective residual a directing manner minimal improved cells provide in BLINCYTO residual is in data and negative
of additional of X older with treatment, BLINCYTO minimal chromosome treatment the negative, of in an This ALL here Philadelphia and B-cell CDXX June, and phase the of positive, pediatric or indication frontline FDA on disease, for based observed the residual the benefit approved consolidation adult for patients status. the regardless disease month survival profound treatment
further to of continue newly in subcutaneous B-ALL impact administration. expand with studies the seek investigation We to through diagnosed of BLINCYTO ongoing and the
in also Our tumor first-in-class STEAPX target clinical a molecule, therapy. zalaritomig, demonstrating importantly, our metastatic T-cell to bispecific bispecific castrate-resistant prostate solid demonstrated cancer, engager activity common ability with CVX profound second a has
this continue the advancing monitoring in enroll are program as fully outpatient now We and enrolled expansion I rapidly dose patients monotherapy have and reduced cohorts. Phase to we
zalaridimig zalaridamig earlier enzalutamide paradigm cancer plan settings. the disease or additional ongoing studies advancing the and prostate treatment of abiraterone Further, we combinations we are with in earlier while of study in
fibroblast To In regard study of III completed bemarituzumab we establishing potential out combination advances, further major sum, directed in round BLINCYTO, administered FORTITUDE in Phase have leading frontline bispecific cancer. with antibody we IIb receptor IMDELLTRA, a platform. oncology, first-in-class of factor of as enrollment cell ZALARIDAMIG the broad a our engager T chemotherapy gastric monoclonal growth XXX,
oral also for both PRMTX as AMG We therapies. solid in a our with MTAP XXX, advancing combination rapidly tumors are inhibitor monotherapy and no other developed
dose ESMO initial be solid I patients Phase AMG MTAP the presented in dose XXX tumors in from escalation data study September. will Additional and of expansion with at
to FDA share the has pleased are orphan XXX AMG the cancer. to we treatment Lastly, for an also that pancreatic designation granted of drug
Turning to inflammation.
in severe patients III arising actively Together with planning of encouraged with COPD. are our data the AstraZeneca, We by in moderate from to very Phase are Phase development study II COPD. TEZSPIRE we for
with the We by are characterized recently FDA designation COPD, that to also pleased add-on Breakthrough very maintenance TEZSPIRE, phenotype. to Therapy granted the an a announce as moderate treatment of eosinophilic severe patients
expected continue Beyond studies esophagitis and chronic this eosinophilic separate data COPD, we where are nasal in top explore with polyps, rhinosinusitis in TEZSPIRE in later line year. to Phase III
of moderate monotherapy rocutinlimab T a ROCKET cell Five over receptor. rebalancing is program monoclonal dermatitis. targeting III HX. studies moderate with readout are data successfully severe And the X dermatitis. placebo of has program now Phase Turning it atopic HORIZON first-in-class ROCKET ongoing antibody comprehensive versus patients The enrolled part in X,XXX III anticipated with rocutinlumab with to to OXXX severe evaluates rocutinlumab fully atopic enrolled. to Phase study, this The adults in
dermatitis, Perrigo explore as we the potential in asthma have III rocutinlumab Phase study atopic in a indications to of moderate a in Beyond additional nodularis. well study and to II initiated as severe Phase continue
X-month pipeline diseases. disease for to therapy with encouraged action depleting every schedule. of very opportunities. Shifting differentiated therapies, chronic efficacy be a our a by This a autoimmune late-stage dosing could CDXX UPLIZNA, B-cell of with than several to advancements are IV rare important other durable rare we mechanism the disease, inflammatory mid- convenient offers
the identified. and disease. safety its the at activities to top III randomized Phase results disease endpoint, treatment This placebo-controlled of no clinical the filing presented XX-week risk excited demonstrate population. signals the to the and in for placebo meeting. trial an Recently, compared a new evaluating met IgGX-related are from medical during in first as GX of UPLIZNA will Regulatory XX% controlled key underway were efficacy data trial trial efficacy flare, announce patient immunoglobulin IgGX-related full and future astonishing reduction trial also met of The secondary a line be disease we related safety endpoints window. were from positive the All to is showing primary the were
gravis a experience MINT disease the III a The and are who severity study. MINT comparable generalized studying We treatment myasthenia comparable recently study generalized with also UPLIZNA in evaluating other in a Phase through are efficacy the therapies. UPLIZNA of of to and gravis, ongoing is approved biologic safety patients myasthenia
specific this muscle patients. We the serotypes positive predominant UPLIZNA kinase acetycholine in in and disease, antibody are investigating tyrosine that positive receptor drive X
demonstrate from is therapeutics steroids trial benefit from half forward to of program our the had Patients XXXX. who directed we the efficacy entered with the of attempting steroids. cell-mediated CDXX-directed MINT treatment in development even to therapies, in disease MINT impact blinatumumab. biological only specified insights are CDXX XX protocol We second UPLIZNA small a and of targeting weeks. To readout and patients paper the the data launching more serious B look while removing studies trial diseases, by compelled on of both to inferences by positive inflammatory suffering autoimmune CDXX a expand
advancing exciting an well and field. with strong X we in lead are and capabilities well-characterized assets, positioned promising very inflammatory in This is disease to space this Amgen's rapidly
will We due these to more have about programs say . in course.
as the a for registration-enabling May, XXX, ABP biosimilar approved a MacemVY to to the [ interchangeable and and candidate biosimilar studies XXX first Opdivo. in to ABP or SOLIRIS are Also FDA development, underway KEYTRUDA ] candidate biosimilar in Lastly, eculizumab. biosimilar
and facing their patients serious commitment the momentous our closing, sense my medicines. through collaboration and illness, service for business our growing Amgen their thank this like both potential of to to colleagues best-in-class portfolio research strong this of and to impact first-in-class and focus intense during I'd spirited of In year their
I'll over now turn it to Peter.
